Comparative Pharmacology
Head-to-head clinical analysis: EVZIO AUTOINJECTOR versus NALOXONE HYDROCHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVZIO AUTOINJECTOR versus NALOXONE HYDROCHLORIDE AUTOINJECTOR.
EVZIO (AUTOINJECTOR) vs NALOXONE HYDROCHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
Initial: 0.4 mg or 2 mg intramuscularly (IM) or subcutaneously (SC); may repeat every 2-3 minutes as needed. For autoinjector: 2 mg single dose, administer IM or SC into anterolateral thigh; may repeat every 2-3 minutes with a new device if no response. Max total dose: 10 mg.
None Documented
None Documented
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Terminal elimination half-life approximately 1 to 1.5 hours in adults. In neonates, half-life is prolonged (about 3 hours). Clinical context: due to short half-life, repeated doses or continuous infusion may be needed for opioid overdose with long-acting opioids.
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites. Less than 1% excreted unchanged in urine. Fecal excretion minimal (<5%).
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist